Q32 Bio Inc.
QTTBNasdaq
$15.05
↓ -1.1%Jul 17 close · end-of-day
Price
1Y↑ +441.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$212.1M
Enterprise Value
$161.4M
P/E
5.4
P/S
—
P/B
4.6
EV/EBITDA
7.4
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
$33.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
71.7%
ROIC
—
Debt / Equity
—
Net Cash
$50.8M
Return 1Y
+548.7%
Company profile
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
- CEO
- Jodie Pope Morrison
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 39
- Headquarters
- Massachusetts
- Website
- www.q32bio.com
Management & directors
- Kalowski LeeCFO and President
- Morrison Jodie PopeCEO
- Violette Shelia M.Chief Scientific Officer
Roles derived from SEC Form 4 filings.
Earnings
QTTB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.54↓ -40.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.7M | $34.0M | $3.2M | -$6.7M | $0.00 | $53.7M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$130.3M | -$95.9M | -$133.3M | -$48.3M | -$66.1M | $16.9M |
| Net income | -$128.7M | -$95.8M | -$5.0M | -$53.7M | -$47.7M | $29.8M |
| Diluted EPS | — | -$1.73 | -$0.09 | -$153.96 | -$6.58 | $2.42 |
| Operating cash flow | -$94.3M | -$109.8M | -$113.7M | -$18.7M | -$67.7M | -$33.5M |
| Free cash flow | -$98.1M | -$112.1M | -$114.9M | -$18.7M | -$67.8M | -$33.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -4821.0% | -282.4% | -4154.6% | 725.5% | — | 31.5% |
| Net margin | -4762.9% | -281.9% | -156.0% | 807.4% | — | 55.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$17.9M | -$18.8M | -$14.5M | -$12.2M | -$9.2M | -$7.6M | $45.9M | -$7.7M |
| Net income | -$17.0M | -$17.6M | -$14.2M | -$11.0M | -$9.5M | -$7.4M | $57.7M | -$7.6M |
| Diluted EPS | -$1.42 | -$1.46 | $2.63 | -$0.90 | -$0.78 | -$0.60 | $4.70 | -$0.54 |
| Operating cash flow | -$22.2M | -$19.5M | -$11.4M | -$12.5M | -$10.7M | -$4.2M | -$6.2M | -$6.3M |
| Free cash flow | -$22.2M | -$19.6M | -$11.4M | — | — | -$4.2M | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 20, 2026
Jul 15, 2026
Jul 14, 2026
- 6d agoQ32 Bio stock surges 83% on positive alopecia drug trial dataqz.com
- 6d agoQ32 Bio (QTTB) After Positive Trial Data Is It A Buy Or Already Fairly Valuedfinance.yahoo.com
- 6d agoWhy Did AAPL, QTTB, CSX Stocks Surge To 52-Week Highs Today?stocktwits.com
- 6d agoWhy Q32 Bio Stock Skyrocketed Todayfool.com
Jul 13, 2026
- 6d agoQTTB Stock Clocks Best Day In A Year Following Positive Alopecia Data — Analyst Sees Further 200% Upsidestocktwits.com
- 7d agoQ32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrantsfinance.yahoo.com
- 7d agoTop Midday Gainersfinance.yahoo.com
- 7d agoQ32 Bio’s Bempikibart Shows Durable Hair Regrowth in Phase 2 Alopecia Studymarketbeat.com
- 7d agoQ32 Bio Shares Jump 60% After Positive Mid-Stage Alopecia Trial Results (QTTB)investorshub.advfn.com
- 7d agoQ32 bounces back to claim study success for alopecia drugbiopharmadive.com
- 7d agoQ32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areatafinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Manke Isaac | Option exercise | 53,521 | $2.80 | $149,858.80 | filing |
| 2026-05-28 | ORBIMED ADVISORS LLC | Buy | 1,250,000 | $8.00 | $10.0M | filing |
| 2026-05-28 | Xu Diyong | Buy | 1,250,000 | $8.00 | $10.0M | filing |
| 2026-05-28 | ORBIMED ADVISORS LLC | Buy | 625,000 | $8.00 | $5.0M | filing |
| 2026-05-28 | Xu Diyong | Buy | 625,000 | $8.00 | $5.0M | filing |
| 2026-02-25 | Morrison Jodie Pope· CEO | Sale | 9,896 | $4.51 | $44,674.50 | filing |
| 2026-02-25 | Kalowski Lee· CFO and President | Sale | 3,995 | $4.51 | $18,035.03 | filing |
| 2026-02-25 | Violette Shelia M.· Chief Scientific Officer | Sale | 2,815 | $4.51 | $12,708.04 | filing |
| 2026-02-24 | Violette Shelia M.· Chief Scientific Officer | Award | 37,500 | $0.00 | $0.00 | filing |
| 2026-02-24 | Kalowski Lee· CFO and President | Award | 53,250 | $0.00 | $0.00 | filing |
| 2026-02-24 | Morrison Jodie Pope· CEO | Award | 132,000 | $0.00 | $0.00 | filing |
| 2025-12-02 | Morrison Jodie Pope· CEO | Sale | 22,506 | $3.46 | $77,870.76 | filing |
| 2025-12-02 | Kalowski Lee· CFO and President | Sale | 9,072 | $3.46 | $31,395.47 | filing |
| 2025-08-26 | Morrison Jodie Pope· CEO | Sale | 10,494 | $1.80 | $18,899.69 | filing |
| 2025-08-26 | Kalowski Lee· CFO and President | Sale | 4,240 | $1.80 | $7,636.24 | filing |
| 2025-08-26 | Violette Shelia M.· Chief Scientific Officer | Sale | 2,990 | $1.80 | $5,384.99 | filing |
Latest 16 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.